Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

*This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein do not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**Securities Act**"), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein will be offered and sold outside the United States in reliance on Regulation S under the Securities Act and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein is being or will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*

藥明康德
WuXi AppTec

WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

ADJUSTMENT TO THE CONVERSION PRICE OF U.S.$500,000,000 ZERO COUPON GUARANTEED CONVERTIBLE BONDS DUE 2025

(Stock Code: 5265)

References are made to the (i) announcements of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the "**Company**") dated October 8, 2024 and October 21, 2024 in relation to, among other things, the issue of U.S.$500,000,000 zero coupon guaranteed convertible bonds due 2025 (the "**Bonds**"); (ii) the circular of the Company dated March 26, 2025 (the "**Circular**") and the poll results announcement of the Company dated April 29, 2025 (the "**Poll Results Announcement**") in relation to, among other things, the 2024 Profit Distribution and the 2025 Special Dividend Distribution; and (iii) the announcement of the Company dated May 6, 2025 in relation to the adjustment to the total amount of the profit distribution under the 2024 Profit Distribution and the 2025 Special Dividend Distribution. Unless otherwise stated, the terms used in this announcement shall have the same meanings as defined in the Circular.

As disclosed in the Circular, the Poll Results Announcement and the announcement of the Company dated May 6, 2025, the Company is implementing the 2024 Profit Distribution and the 2025 Special Dividend Distribution which involve (i) a final dividend of RMB9.8169 (inclusive of tax) for every 10 Shares (representing an aggregate amount of RMB2,832,309,813.65 (inclusive of tax)); and (ii) a special dividend of RMB3.5000 (inclusive of tax) for every 10 shares (representing an aggregate amount of RMB1,009,797,833.10 (inclusive of tax)).

Pursuant to the terms and conditions of the Bonds, the price at which H Shares will be issued upon conversion ("**Conversion Price**") is subject to adjustment for, among other things, capital distributions made by the Company. The Company therefore announces that the Conversion Price of the Bonds will be adjusted from HK$80.02 per H Share, being the initial Conversion Price to HK$78.28 per H Share (the "**Adjusted Conversion Price**") as a result of the approval of the payment of the 2024 Profit Distribution and the 2025 Special Dividend Distribution by the Shareholders at the 2024 AGM with effect from May 24, 2025, being the day immediately after the record date for determining H Shareholders' entitlement to the 2024 Profit Distribution and the 2025 Special Dividend Distribution. Save as disclosed above, all other terms of the Bonds remain unchanged.

Assuming full conversion of the Bonds at the Adjusted Conversion Price, the H Shares that may be convertible and issuable under the Bonds will increase from approximately 48,522,244 H Shares to approximately 49,600,792 H Shares, representing approximately 12.81% of the total issued H share capital of the Company as at the date of this announcement and approximately 11.36% of the enlarged total issued H share capital of the Company resulting from the full conversion of the Bonds. The additional 1,078,548 H Shares issuable in the event of a full conversion of the Bonds after the Adjusted Conversion Price becoming effective will be allotted and issued by the Company pursuant to the general mandate sought and granted at the 2024 AGM held on April 29, 2025.

This announcement also serves as a notification to the holders of the Bonds in respect of the adjustment to the Conversion Price in accordance with the trust deed constituting the Bonds entered into between the Company and Citicorp International Limited on October 21, 2024.

Any holder of the Bonds who is in doubt as to the action to be taken should consult his/her/its stockbroker, bank manager, solicitor, professional accountant or other professional adviser.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, May 23, 2025

As at the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

* *For identification purposes only*